Pharmaceutical stability of compounded acetylcholine chloride intraocular solution for intracoronary provocative vasospasm testing - Takeaways - MDSpire

Pharmaceutical stability of compounded acetylcholine chloride intraocular solution for intracoronary provocative vasospasm testing

  • By

  • Killian J. McCarthy

  • Ryan Greenhalgh

  • Erica MacDonald

  • Laura Cedro

  • Duane Pinto

  • Margaret Stephan

  • Eric A. Osborn

  • June 3, 2026

  • 0 min

Share

  • 1

    This study assesses the stability of compounded acetylcholine (ACh) intraocular solutions for use in provocative coronary vasospasm testing.

  • 2

    ACh solutions were compounded using a 7-step method and stored at ambient conditions to simulate cardiac catheterization laboratory settings.

  • 3

    The compounded ACh solution maintained a pH of 4.2 and met USP specifications for particulate matter across all time points.

  • 4

    High-performance liquid chromatography showed that 96.7% of the initial ACh was retained after 12 hours, satisfying USP stability criteria.

  • 5

    The study establishes a simplified compounding approach for generating an intracoronary ACh formulation for use within 12 hours.

Original Source(s)

Pharmaceutical stability of compounded acetylcholine chloride intraocular solution for intracoronary provocative vasospasm testing

  • by Killian J. McCarthy, Ryan Greenhalgh, Erica MacDonald, Laura Cedro, Duane Pinto, Margaret Stephan, Eric A. Osborn

  • June 3, 2026

Related Content

Electroacupuncture alleviates myocardial ischemia-reperfusion injury by targeting and inhibiting NLRP3 inflammasome-mediated cardiomyocyte pyroptosis via serum exosomal miR-22-3p

Incorrect eTable 9 in Supplement 1

  • June 1, 2026

Pan-immune-inflammation value for risk stratification of adverse cardiovascular outcomes in acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis